Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... physical inactivity are all unequivocally identified as fuel for a growing epidemic of hypertension, high cholesterol, obesity and diabetes, all associated with a raised risk of both heart ... thromboembolic stroke as a result of atrial fibrillation receive effective prophylactic therapy."According to the World Stroke Organization, stroke now accounts for almost ...
2009 NOV 23 ... contact F. Zannad, INSERM, Departement of Cardiology, CIC9501 and U961, CHU Nancy, Hypertension and Heart Failure Unit, CHU, Nancy Universite, 54500 Vandoeuvre les Nancy, France. ... New investigation results, 'Heart failure burden and therapy,' are detailed in a study published in Europace. "Heart failure (HF) is a syndrome ...
2009 NOV 23 ... factor-alpha (TNF-alpha) may be an important link between placental ischemia and hypertension in preeclampsia. We examined the effect of 17-hydroxyprogesterone caproate (17-OHP) on ... Caproate, Hypertension, Ischemia, Necrosis, Pharmaceuticals, Progesterone, Therapy, Treatment, University of Mississippi Medical Center. This article was ...
2009 NOV 23 ... Keywords: Country:Brazil, Blood Pressure, Dermatology, Diabetes, Drugs, Hypertension, Itraconazole, Pharmaceuticals, Pharmacological, Sporotrichosis, Terbinafine ... that 250 mg/day terbinafine is an effective and well-tolerated alternative to drug therapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible." ...
2009 NOV 23 ... patients after the introduction of combined antiretroviral therapy, pulmonary arterial hypertension (PAH) has become an important cause of morbidity. As the awareness of PAH has increased, ...
2009 NOV 23 ... often have an increased incidence of cardiovascular disease (CVD) risk factors such as hypertension and dyslipidemia. Both type 2 diabetes and obesity are independent risk factors for ... Diabetes Mellitus, Obesity, Obesity and Diabetes, Peptidase, Proteins, Proteomics, Therapy, Treatment, Type 2 Diabetes Mellitus, Weight Gain, Columbia University. ...
2009 NOV 23 ... Bomback and colleagues published their study in American Journal of Hypertension (Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and ... concluded: "This review examines what is presently known about ACEI/ARB combination therapy and explores alternative combination strategies that include DRIs and mineralocorticoid ...
2009 NOV 23 ... "Using a deoxycorticosterone acetate (DOCA)/salt-low renin rat model, which exhibits hypertension, proteinuria, endothelial dysfunction, and intrauterine growth restriction (IUGR), we ... Hypertension, Mycophenolate Mofetil, Pharmaceuticals, Pregnancy-Induced Hypertension, Therapy, Treatment, Texas A&M University, Medical Department. This article was ...
2009 NOV 23 ... Barbieri and colleagues published their study in the Journal of Clinical Hypertension (Diuretic-Induced Potassium Depletion and Glucose Intolerance Are Not Related to ... the renin-angiotensin-aldosterone system (RAAS). To assess the hypothesis that diuretic therapy in MS patients through further stimulation of RAAS would elicit greater potassium (K) ...
2009 NOV 23 ... herb traditionally used in Japan, Korea and China for the treatment of hypertension and alcoholism," scientists in Bangkok, Thailand report. "We evaluated ... Addiction Medicine, Mental Health, Hypertension, Salmonella, Alternative Medicine, Therapy, Treatment, Chulalongkorn University. This article was prepared by Biotech ...
2009 NOV 23 ... (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." ... patients with diabetes uncontrolled for LDL-C were maintained on suboptimal atorvastatin therapy (mean final dose: 29.9 mg vs maximum of 80 mg)," wrote K.C. Ferdinand and colleagues. ...
2009 NOV 24 ... duration increased by 4.2 minutes for diabetes mellitus, by 3.7 minutes for essential hypertension and by 5.9 minutes for arthropathies (joint diseases). "Comparing the ... in which patients did not receive these services, while providing appropriate medication therapy was not associated with longer visit duration. "Although it is possible ...
2009 NOV 23 ... And patients were classified as having risk factors if they received codes for diabetes, hypertension, hyperlipidemia, or smoking. Controls without psoriasis were randomly selected from the ... "with psoriasis were classified as severe if they ever received a systemic therapy. And patients were classified as having risk factors if they received codes for ...
2009 NOV 23 ... patients were identified with a mean age of 73 years and with multiple comorbidities (hypertension, malnutrition, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery ... Heart Bypass Surgery, Heart Disease, Hypertension, Malnutrition, Surgical Technology, Therapy, Tissue Engineering, Treatment, Vascular Graft, Wound Infections. This ...
2009 NOV 23 ... rights to Rescula®, an FDA-approved treatment for open-angle glaucoma and ocular hypertension. Sucampo plans to re-launch Rescula in 2010, and to develop it for additional ophthalmic ... Pharmaceutical Company, Pharmaceuticals, Sucampo Pharmaceuticals Inc., Therapies, Therapy, Treatment, Sucampo Pharmaceuticals Inc. This article was prepared by ...
2009 NOV 23 ... localized in vivo measurement of changes in renin-angiotensin system (RAS) involved in hypertension and some neurological diseases. "We continue to be very pleased with the ... Neurological Disease, Oncology, Pharmaceuticals, Pharmacokinetics, Protease, Renin, Therapy, Treatment, VisEn Medical Inc. This article was prepared by Pain & Central ...
2009 NOV 23 ... using the company's proprietary structure-based design platform. In animal models of hypertension, VTP-27999 demonstrated significant and sustained reductions in blood pressure, as well ... Metabolic Disease, Pharmaceutical Business, Pharmaceutical Company, Pre-Trials Research, Therapy, Treatment, Vitae Pharmaceuticals, Vitae Pharmaceuticals Inc. This article ...
2009 NOV 23 ... and sustained reductions in blood pressure in patients with multidrug-resistant hypertension. The Symplicity HTN-1 study, sponsored by Ardian, Inc. (Palo Alto, CA), was a pilot ... Restenosis, Self-expanding Stent, Stent System, Stroke, Surgery, Surgical Technology, Therapy, Treatment, U.S. Food and Drug Administration, VIVA Physicians Inc. This ...
2009 NOV 29 ... increases after menopause, partly because of ovarian hormone deficiency that favours hypertension, diabetes, hyperlipidemia, central obesity and the metabolic syndrome.In the ... underrepresentation is particularly noticeable in the fields of cholesterol-lowering therapy, ischaemic heart disease and heart failure.Professor Roberto Ferrari, ...
